

Pourhassan Nader
Form 4
November 16, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Pourhassan Nader

(Last) (First) (Middle)
1111 MAIN STREET, SUITE 660
(Street)

VANCOUVER, WA 98660

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [CYDY]

3. Date of Earliest Transaction
(Month/Day/Year)
11/16/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
President and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | | Code V | Amount | (A) or (D) | Price |
| Common Stock | 11/16/2018 | | D | | 161,489 | D | <u>(1)</u> <u>(2)</u> 0 |
| Common Stock | 11/16/2018 | | D | | 15,750 | D | <u>(1)</u> <u>(2)</u> 0 |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Edgar Filing: Pourhassan Nader - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|-----|--|-----------------|---|----------------------------|
| | | | | | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Options (right to buy) | \$ 0.64 | 11/16/2018 | | D | 200,000 | | 05/29/2018 | 05/29/2019 | Common Stock | 200,000 |
| Stock Options (right to buy) | \$ 2 | 11/16/2018 | | D | 500,000 | | 07/31/2015 | 07/31/2021 | Common Stock | 500,000 |
| Stock Options (right to buy) | \$ 2.75 | 11/16/2018 | | D | 54,545 | | 03/23/2012 | 03/23/2022 | Common Stock | 54,545 |
| Stock Options (right to buy) | \$ 0.9 | 11/16/2018 | | D | 200,000 | | 06/30/2018 | 06/30/2025 | Common Stock | 200,000 |
| Stock Options (right to buy) | \$ 0.87 | 11/16/2018 | | D | 650,000 | | ⁽³⁾ | 11/23/2025 | Common Stock | 650,000 |
| Stock Options (right to buy) | \$ 0.75 | 11/16/2018 | | D | 304,000 | | ⁽³⁾ | 01/04/2026 | Common Stock | 304,000 |
| Stock Options (right to buy) | \$ 1.09 | 11/16/2018 | | D | 600,000 | | ⁽⁴⁾ | 06/01/2026 | Common Stock | 600,000 |
| Stock Options (right to buy) | \$ 0.57 | 11/16/2018 | | D | 300,000 | | ⁽⁵⁾ | 06/01/2027 | Common Stock | 300,000 |
| Stock Options (right to buy) | \$ 0.8 | 11/16/2018 | | D | 600,000 | | 05/31/2017 | 02/15/2023 | Common Stock | 600,000 |

| | | | | | | | | |
|------------------------------|----------|------------|---|-----------|------------|------------|--------------|-----------|
| Stock Options (right to buy) | \$ 0.49 | 11/16/2018 | D | 350,000 | <u>(6)</u> | 06/08/2028 | Common Stock | 350,000 |
| Stock Options (right to buy) | \$ 0.565 | 11/16/2018 | D | 1,000,000 | <u>(7)</u> | 11/08/2028 | Common Stock | 1,000,000 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Pourhassan Nader 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660 | X | | President and CEO | |

Signatures

/s/ Michael D. Mulholland, as
attorney-in-fact

11/16/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.

- (1) Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).
- (2) The options vest upon the achievement of certain strategic milestones specified in the award agreement.
- (3) The options vest in three equal annual installments commencing on June 1, 2017.
- (4) The options vest in three equal annual installments commencing on June 1, 2018.
- (5) The options vest in three equal annual installments commencing on June 1, 2019.
- (6) 50% of the options were fully vested and exercisable as of their issuance date, and 50% of the options vest on April 8, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.